1314 ET - Hims & Hers' launch of generic liraglutide is likely to contribute more to the telehealth platform's growth than offering Eli Lilly's Zepbound, Leerink Partners analyst Michael Cherny tells WSJ. The liraglutide launch comes a month earlier than expected and could help boost quarterly revenue, as the company is looking for alternatives to its compounded semaglutide drug, which the FDA is cracking down on now that shortages of GLP-1s are over. Liraglutide falls more in line with Hims business model of offering affordable treatments, Cherney says, as it would cost around $299 a month vs. $1,899 a month for Zepbound.(katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 13:14 ET (17:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。